Trial Status: Recruiting

A Study of Co-formulated Favezelimab/Pembrolizumab Versus Doctor’s Choice Chemotherapy in PD-1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma

By

The purpose of this study is to compare efficacy of co-formulated favezelimab/pembrolizumab (MK-4280A) with doctor’s choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory, relapsed or refractory classical Hodgkin Lymphoma. The study will also assess the safety and tolerability of co-formulated favezelimab/pembrolizumab. The primary study hypotheses are that co-formulated favezelimab/pembrolizumab is superior to doctor’s … Continued

A Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma

By

The purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage … Continued

A Study of Belzutifan Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post-Nephrectomy

By

The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post-nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect … Continued

Study of Pembrolizumab Versus Chemotherapy in Mismatch Repair Deficient Advanced or Recurrent Endometrial Carcinoma

By

The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy. The primary study hypotheses are that pembrolizumab is … Continued

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

By

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the investigator. The hypotheses are that pembrolizumab plus paclitaxel with or without bevacizumab is superior to … Continued

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumours

By

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumours including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC), and oesophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in … Continued

Efficacy and Safety of Nemtabrutinib in Participants With Haematological Malignancies

By

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with haematological malignancies of chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM).

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumours

By

This study consists of several parts: dose escalation, dose expansion, dose expansion in Chinese participants residing in China, and coformulation. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Arms A and B) and in combination with pembrolizumab (Arm C). Dose expansion is to evaluate the objective response rate … Continued

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumours Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Study

By

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who roll-over into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will roll-over to … Continued

Study of Pembrolizumab and Pembrolizumab With Other Investigational Agents in Participants With High-Risk Non-muscle Invasive Bladder Cancer

By

In this study, participants with high-risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have refused to undergo radical cystectomy, will receive pembrolizumab therapy or pembrolizumab in combination with other investigational agents. The primary study hypothesis is that treatment with pembrolizumab will result in a … Continued